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fx) to the non-involved prostate. Planning constraints used 
were based on institutional procedures as well as from the 
FLAME trial, with small modifications in the boost plans. The 
dose distributions (with/without boost) were used to 
calculate the TCP and NTCP values for each patient. The TCP 
model used apparent diffusion coefficient maps to estimate 
cell densities while the NTCP models used were the 
conventional Lyman model for the rectum (late rectal 
bleeding grade >= 2; Rad. Onc, 73, 21-32, 2004) and the 
Poisson LQ model for the bladder (contracture; Ågren PhD 
thesis, 1995). 
 
Results: The TCP increased from a median (range) of 0.45 
(0.08-0.83) with the conventional approach to 1.0 (no range) 
with the focal boost. While there were only minor differences 
in the rectum NTCPs with vs. without the boost there were 
considerable differences in the NTCP for the bladder for two 
of the patients (more than a doubling of the NTCP with the 
boost; Table 1). These two patients had the index lesion that 
was closest to the bladder. 
 
 
 
 
 
Conclusion: We have established a biological modelling 
based method to identify prostate cancer patients where the 
focal boost cannot be achieved with state of the art photon-
based treatment without a considerable increase in the 
NTCPs. Further work will consider the feasibility of proton 
planning, given both inter- and intra-fractional organ motion 
patterns.  
 
 
 
 
 
 
EP-1727  
A decision support system for localised prostate cancer 
treated by external beam radiation therapy 
S. Walsh
1MAASTRO clinic, Knowledge Engineering, Maastricht, The 
Netherlands 
1, M. Field2, M. Barakat2, L. Holloway3, M. Bailey4, M. 
Carolan4, G. Goozee3, G. Delaney3, A. Miller4, M. Sidhom3, P. 
Lambin1, D. Thwaites2, A. Dekker1 
2University of Sydney, Medical Physics, Sydney, Australia 
3Ingham Institute, Medical Physics, Sydney, Australia 
4Illawarra Cancer Care Centre, Medical Physocs, Wollongong, 
Australia 
 
Purpose or Objective: This study presents a universally 
applicable decision support system (DSS), with respect to the 
prediction of five-year biological no evidence of disease (5y-
bNED) for localised prostate cancer (PCa) patients treated by 
external beam radiation therapy (EBRT). 
 
Material and Methods: To develop a DSS this study utilised 
the traditional approach of model training based upon meta-
analysis data (MAD: n=5218) from the literature with model 
validation based upon routine clinical care data (CCD: n=827) 
from clinics with a rapid learning healthcare (RLHC) 
environment. The following standard clinical features for PCa 
patients were investigated to train and validate a tumour 
control probability model (TCP) and a predictive machine 
learning model (PML): primary tumour stage (T), lymph node 
stage (N), metastasis stage (M), prostate specific antigen 
(PSA), Gleason score (GS), clinical-target-volume (CTV), total 
dose (D), and fractional dose (d). These features were 
selected as they are typically known within all clinics treating 
PCa patients, thus maximising the generalizability of the DSS. 
 
Results: The DSS is comprised of two distinct models. The 
TCP model was found to be well calibrated with poor 
discriminative ability. Training resulted in an adjusted 
weighted R2 value of 0.76, a weighted mean absolute 
residual (wMAR) of 4.7% and an area under the curve (AUC) of 
0.67 [0.65, 0.69]. Validation resulted in an adjusted weighted 
R2 value of 0.51, a wMAR of 2.0% and an AUC of 0.57 [0.51, 
0.63]. Contrastingly, the PML model was found to be poorly 
calibrated with good discriminative ability. Training resulted 
in an adjusted weighted R2 value of 0.27, a wMAR of 8.3% 
and an AUC of 0.66 [0.64, 0.68]. Validation resulted in an 
adjusted weighted R2 value of 0.90, a wMAR of 16.2% and an 
AUC of 0.61 [0.56, 0.65]. Subset analysis shows that the DSS 
performs best in high-risk PCa patients with validation 
resulting in an AUC of 0.66 [60, 0.72] with a wMAR of 1.0%. 
 
Conclusion: A DSS developed with MAD has been validated in 
CCD extracted using RLHC infrastructure. The DSS uses 
standard clinical features to estimate with good accuracy 
(wMAR < 4.7%) and reasonable fidelity (AUC > 0.61) the 5y-
bNED rate and classification, respectively, of PCa patients. 
The performance of the DSS in the validation high-risk PCa 
cohort (wMAR = 1%) and patients (AUC = 0.66) for whom 
therapy could be potentially adapted or individualised based 
on the DSS has clinical relevance and should be prospectively 
validated. 
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Purpose or Objective: The use of biological information on 
tumour control and normal-tissue complications for 
treatment plan optimisation can be used for individualising 
the dose prescription. For patients with prostate cancer, 
moreover, the tumour localisation by means of MR-images 
facilitates the use of such information for a simultaneous 
dose escalation in the so-called dominant intraprostatic 
lesions (DIL), thus further improving the treatment outcomes. 
However, a correct modelling of the tumour-control 
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probability depends on the accuracy of the alpha-beta ratio 
for prostate cancer, the value of which is still a matter of 
discussion in the scientific community. Therefore various 
scenarios should be investigated for understanding the limits 
of the biologically-based dose escalation to the tumour 
during prostate radiotherapy.  
 
Material and Methods: This work investigates the potential 
and limits of biologically-based treatment planning for ten 
prostate-cancer patients with localised disease in the case of 
alpha-beta-ratios of 1.5 Gy, 3 Gy, and 4.5 Gy, respectively. 
The MR images of these patients were used for contouring 
the intraprostatic lesion as GTV and were matched with the 
CT images in EclipseTM. Biologically-based 7-fields IMRT plans 
were optimised by minimising the NTCP for rectal bleeding 
and bladder contracture and by maximising the TCP for the 
GTV. For all patients, the dose prescription for the PTV 
(whole prostate) was 72 Gy in 40 fractions.  
 
Results: The results of this plan-comparison study show that 
the individual GTV dose coverage depends on the alpha-beta 
ratio for prostate cancer, while the calculated dose 
distribution (in particular the mean dose values and the D3%) 
for rectum and bladder are not influenced by this parameter. 
Also, the total dose to the GTV could be individually 
optimised and varied between 76 Gy and 87 Gy, depending on 
the position of the DIL within the prostate. Finally, the 
optimised total dose to the GTV increased when modelling 
the TCP with a lower alpha-beta ratio, with individual 
differences up to 3 Gy. 
 
Conclusion: Biologically-based optimisation tools allow for 
individualised dose escalation in dominant intraprostatic 
lesions and, in principle, could be safely used for the 
treatment planning of prostate cancer. In fact, a variation of 
the alpha-beta ratio for prostate cancer between 1.5 Gy and 
4.5 Gy causes a variation of the dose coverage of the GTV of 
up to about 3 Gy in total, thus showing an acceptable 
robustness of the TCP model with respect to this parameter. 
Biologically-based optimisation tools, finally, have the 
advantage of reducing optimisation time, contouring process, 
and dose hot spots. Studies are currently being carried out in 
order to further validate the TCP and NTCP models for 
prostate cancer treatment in the case of hypofractionated 
schedules. 
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Purpose or Objective: Accuracy of radiotherapy to the 
prostate is often challenged by geometrical uncertainties due 
to inherent organ motion attributed to daily variations of the 
bladder and rectal volumes and contents. This study aims to 
simulate the use of 4D Clarity ultrasound image guidance 
without CBCT imaging to analyse the magnitude and trend of 
prostate motion during treatment (74Gy given in 37 
fractions). The impact of CBCT imaging and verification time 
on prostate motion will be analysed. 
 
Material and Methods: 175 intra-fraction monitoring sessions 
from 5 patients who underwent radical prostate volumetric 
modulated arc therapy (VMAT) monitored using 4D 
transperineal ultrasound scan (TPUS) resulted in a total of 
1461.2min of data (184,085 positioning points) being 
analysed. All patients were instructed to comply with a full 
bladder protocol (i.e. 300-450ml in 30-45min) without 
specific rectal preparation protocol. Mean prostate motion 
was calculated and analysed in relation to time in the 
subsequent fractions. Overall treatment time was defined 
from acquisition of CBCT to treatment beam off time and 
imaging time was defined from time of CBCT acquisition to 
first beam on. Imaging time was subtracted from the overall 
treatment time for analysis of prostate motion without CBCT 
for verification. The remaining duration was representative 
of treatment time using 4D Clarity ultrasound image guidance 
alone. The impact of CBCT imaging and verification time on 
prostate motion was analysed. 
 
Results: Mean (median) imaging and overall treatment time 
was 4.6min (4.4 min) and 8.4min (8.3 min) respectively. 
Mean (median) prostate motion during overall treatment time 
was 0.7mm (0.6mm) Inf, 1.0mm (0.9mm) Post and 0.1mm 
(0.2mm) Lt respectively. Mean prostate motion without CBCT 
was 0.6mm (0.5mm) Inf, 0.9mm (0.8mm) Post and 0.1mm 
(0.1mm) Lt. Figure 1 demonstrates the observed prostate 
displacement over time in a single session from one of the 
patients. In general, the mean (median) maximum prostate 
drift during actual treatment alone tends to trend towards 
the following directions at 3.6mm (3.4mm) Inf, 7.4mm 
(5.2mm) Ant and 2.7mm (2.8mm) Lt. Magnitude of the 
median maximum prostate displacement increased relatively 
by 38.4%, 16.7% and 46.6% in the Inf, Ant and Lt directions 
respectively with added imaging time. 
 
 
 
Conclusion: Prolonged overall treatment time due to CBCT 
imaging and verification time increases the intra-fraction 
prostate motion. We propose the use of 4D Clarity TPUS in 
place of TPUS with CBCT to reduce imaging time before 
radiotherapy to reduced total verification time leading to 
reduced prostate movement. Consequently, the magnitude of 
intra-fraction prostate motion could be reduced from 
reduced image acquisition and reconstruction time. This 
reduces the total in room time per patient and maximises 
patient through-put and treatment efficiency which is 
important in a busy radiotherapy centre. 
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Purpose or Objective: To investigate the Geometric 
difference between six different ITVx delineation methods 
from 4D-CT  
for patients with Non Small Cell Lung Cancer (NSCLC) treated 
with Stereotactic Ablative Radiotherapy  
(SABR) technique. 
 
Material and Methods: Between December 2013 and March 
2014, 46 patients who underwent SABR were includedin  
this retrospective study. All patients underwent imaging 
acquisition with 4D-CT scans, The tu- 
mor motion range, volume , marching index (MI) and 
encompassment index (EI) of ITV10, IT- 
